Myelodysplastic syndrome (deletion 5q) - lenalidomide [ID480]: evaluation report
Contents:
01. NICE's response to comments on the Appraisal Consultation Document (ACD)
02. Consultee comments on the ACD - Celgene
03. Consultee comments on the ACD - MDS UK and Leukaemia Care
04. Consultee comments on the ACD- RCP and British Committee for Standards in Haematology
05. Public comments on the ACD received through the NICE website
Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.
It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.
If you have any feedback on the new format please contact the Project Manager for this appraisal.
Myelodysplastic syndrome (deletion 5q) - lenalidomide [ID480]: evaluation report
19 August 2014 (2.3 Mb 26 sec) |
This page was last updated: 19 August 2014